Brief: Isofol Presents Conclusions From The In-Depth Analysis Of The Agent Study

Isofol Medical AB (publ)

04/07/2023 09:13

July 4 (Reuters) - Isofol Medical AB (publ)  ISOFOL.ST :
    * ISOFOL PRESENTS CONCLUSIONS FROM THE IN-DEPTH ANALYSIS OF
THE
AGENT STUDY
    * RECENT AGENT STUDY DID NOT SHOW A STATISTICALLY
SIGNIFICANT
DIFFERENCE IN EFFICACY BETWEEN ARFOLITIXORIN AND STANDARD
TREATMENT GIVEN IN CONTROL ARM
    * ISOFOL HAS THEREFORE DECIDED TO CONTINUE DEVELOPMENT OF
ARFOLITIXORIN AND IS INTENSIFYING PREPARATIONS FOR A POSSIBLE
START OF A MINOR CLINICAL STUDY
    * RESULTS FROM ANALYSIS SUPPORT HYPOTHESIS THAT A DIFFERENT
DOSE
AND ADMINISTRATION REGIMEN HAS POTENTIAL TO IMPROVE EFFICACY OF
COMPANY'S DRUG CANDIDATE ARFOLITIXORIN

Source text for Eikon:  ID:nWkr4xwplf 
Further company coverage:  ISOFOL.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))